Aldeyra Thinks It May Have Broadly Applicable Retinitis Pigmentosa Therapy
Executive Summary
Data from a small Phase II study show that Aldeyra’s methotrexate formulation may address the underlying cause of 20%-30% of RP cases. The drug recently was denied US FDA approval in a rare ocular cancer.